Related Experiment Videos
Durability of serological remission in chronic hepatitis C treated with interferon-alpha-2B
Insights
A 13.6% sustained response rate was observed in chronic hepatitis C patients treated with interferon. These patients maintained normal ALT and undetectable hepatitis C virus RNA for over 48 months post-therapy.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis C virus (HCV) infection poses a significant global health burden.
- Interferon therapy has been a cornerstone treatment for chronic hepatitis C, but long-term efficacy data require ongoing assessment.
- Understanding sustained virological response is crucial for managing chronic hepatitis C.
Purpose of the Study:
- To evaluate the long-term biochemical and virological outcomes of Canadian patients with chronic hepatitis C following interferon therapy.
- To determine the sustained remission rates and factors influencing treatment response in chronic hepatitis C patients.
Main Methods:
- A cohort of 36 Canadian patients with chronic hepatitis C received interferon-alpha-2B therapy.
- Patients were followed for a median of 37.2 months post-treatment, with assessments at 6 months and end-of-study.
- Serum alanine aminotransferase (ALT) and hepatitis C virus (HCV) RNA levels were measured using branched DNA assay and polymerase chain reaction.
Main Results:
- A sustained treatment response, defined by normal ALT and undetectable HCV RNA at 6 months post-therapy, was achieved by 13.6% (5/36) of patients.
- All five responders maintained serological remission throughout the median follow-up of 48.2 months.
- No significant differences were found between responders and non-responders regarding baseline characteristics or interferon dosage.
Conclusions:
- Interferon therapy resulted in a sustained virological response in 13.6% of chronic hepatitis C patients.
- Achieving normal ALT and undetectable HCV RNA 6 months post-treatment predicted long-term remission.
- These findings highlight the potential for durable responses in a subset of patients treated with interferon.
Objective:
We assessed the long-term effect of a course of interferon therapy on the biochemical and virological markers of Canadian patients with chronic hepatitis C.
Methods:
Thirty-six patients with chronic hepatitis C were treated with a median total dose of interferon-alpha-2B of 181.0 million U (range 109.0-384.0 million U) and were followed for a median of 37.2 months (range 12.0-94.2 months) after completing treatment. All patients received an initial 16 wk of interferon at a dose of 3 million U three times weekly; this was followed by either no further interferon or by 8 wk more at doses ranging from 1.5 to 10.0 million U three times weekly. Serum alanine aminotransferase (ALT) and hepatitis C virus (HCV) RNA levels were measured before interferon therapy, 6 months after treatment, and at the end of follow-up for each patient. HCV RNA was analyzed by branched DNA 1.0 assay and, if undetectable, by polymerase chain reaction. HCV genotyping was performed on serum samples.
Results:
Five (13.6%) of the 36 patients had a sustained treatment response, defined as normal ALT and undetectable viremia 6 months after treatment. All five patients remained in serological remission to the end of their follow-up, a median of 48.2 months (range 23.0-66.2 months) after interferon therapy. Responders were similar to nonresponders in age, gender, initial ALT and serum HCV RNA levels, pretreatment histology, and total dose of interferon received.
Conclusions:
In patients with chronic hepatitis C, 13.6% had normal ALT and undetectable serum HCV RNA 6 months after finishing interferon therapy. These patients remained in serological remission to the end of their follow-up, 48.2 months after interferon therapy.